Evofem Biosciences (EVFM) Competitors $0.01 0.00 (-2.13%) (As of 12:56 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSustainabilityTrends EVFM vs. GNPX, XCUR, CELZ, VCNX, ENSC, BCDA, SHPH, EVOK, LIXT, and IMCCShould you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include Genprex (GNPX), Exicure (XCUR), Creative Medical Technology (CELZ), Vaccinex (VCNX), Ensysce Biosciences (ENSC), BioCardia (BCDA), Shuttle Pharmaceuticals (SHPH), Evoke Pharma (EVOK), Lixte Biotechnology (LIXT), and IM Cannabis (IMCC). These companies are all part of the "pharmaceutical products" industry. Evofem Biosciences vs. Genprex Exicure Creative Medical Technology Vaccinex Ensysce Biosciences BioCardia Shuttle Pharmaceuticals Evoke Pharma Lixte Biotechnology IM Cannabis Evofem Biosciences (NASDAQ:EVFM) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Which has more risk & volatility, EVFM or GNPX? Evofem Biosciences has a beta of -0.79, suggesting that its share price is 179% less volatile than the S&P 500. Comparatively, Genprex has a beta of -1.32, suggesting that its share price is 232% less volatile than the S&P 500. Is EVFM or GNPX more profitable? Evofem Biosciences has a net margin of 341.16% compared to Genprex's net margin of 0.00%. Evofem Biosciences' return on equity of -91.97% beat Genprex's return on equity.Company Net Margins Return on Equity Return on Assets Evofem Biosciences341.16% -91.97% 594.75% Genprex N/A -318.57%-224.95% Does the media prefer EVFM or GNPX? In the previous week, Genprex had 2 more articles in the media than Evofem Biosciences. MarketBeat recorded 4 mentions for Genprex and 2 mentions for Evofem Biosciences. Evofem Biosciences' average media sentiment score of 0.88 beat Genprex's score of -0.01 indicating that Evofem Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evofem Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genprex 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in EVFM or GNPX? Evofem Biosciences received 63 more outperform votes than Genprex when rated by MarketBeat users. Likewise, 69.50% of users gave Evofem Biosciences an outperform vote while only 65.25% of users gave Genprex an outperform vote. CompanyUnderperformOutperformEvofem BiosciencesOutperform Votes26269.50% Underperform Votes11530.50% GenprexOutperform Votes19965.25% Underperform Votes10634.75% Which has higher valuation & earnings, EVFM or GNPX? Evofem Biosciences has higher revenue and earnings than Genprex. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvofem Biosciences$18.22M0.08$52.98M-$0.50-0.03GenprexN/AN/A-$30.86MN/AN/A Do analysts recommend EVFM or GNPX? Genprex has a consensus target price of $10.00, suggesting a potential upside of 365.12%. Given Genprex's stronger consensus rating and higher probable upside, analysts clearly believe Genprex is more favorable than Evofem Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evofem Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Genprex 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in EVFM or GNPX? 0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 14.1% of Genprex shares are held by institutional investors. 0.2% of Evofem Biosciences shares are held by company insiders. Comparatively, 8.5% of Genprex shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryEvofem Biosciences beats Genprex on 9 of the 15 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Evofem Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVFM vs. The Competition Export to ExcelMetricEvofem BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.42M$6.69B$4.97B$8.42BDividend YieldN/A7.94%7.49%4.16%P/E Ratio-0.0310.92121.6116.46Price / Sales0.08356.711,518.5391.66Price / Cash0.0146.0936.9033.53Price / Book-0.015.324.585.14Net Income$52.98M$148.76M$112.22M$223.04M7 Day PerformanceN/A1.76%115.58%3.22%1 Month PerformanceN/A13.95%129.27%8.47%1 Year PerformanceN/A35.21%157.18%28.62% Evofem Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVFMEvofem Biosciences0.7668 of 5 stars$0.01-2.1%N/A-80.6%$1.39M$11.39M-0.03120Gap DownGNPXGenprex4.2255 of 5 stars$2.15-4.4%$10.00+365.1%-83.2%$5.57MN/A0.0020XCURExicure2.3665 of 5 stars$3.16+4.3%N/A+401.6%$5.47M$28.83M-0.6950CELZCreative Medical Technology1.2651 of 5 stars$4.02-2.9%N/A-13.5%$5.35M$17,000.00-0.995Gap UpVCNXVaccinex1.3851 of 5 stars$2.95+5.7%N/A-77.3%$5.10M$356,000.00-0.0540Upcoming EarningsENSCEnsysce Biosciences1.0153 of 5 stars$0.65+12.1%N/A-34.3%$5.08M$2.23M-0.2310Gap UpHigh Trading VolumeBCDABioCardia2.5891 of 5 stars$2.39+2.6%$25.00+946.0%-60.2%$5.08M$428,000.00-0.4416Gap UpSHPHShuttle Pharmaceuticals1.3368 of 5 stars$1.67-10.7%N/AN/A$4.93MN/A-0.495Upcoming EarningsEVOKEvoke Pharma0.7224 of 5 stars$5.80-0.9%N/A-59.4%$4.75M$7.53M-0.364Analyst ForecastLIXTLixte Biotechnology0.58 of 5 stars$2.02-4.3%N/A-32.7%$4.75MN/A-1.133IMCCIM Cannabis0.3642 of 5 stars$1.97-5.3%N/A-30.3%$4.65M$36.15M-0.51340Upcoming EarningsPositive NewsHigh Trading Volume Related Companies and Tools Related Companies Genprex Alternatives Exicure Alternatives Creative Medical Technology Alternatives Vaccinex Alternatives Ensysce Biosciences Alternatives BioCardia Alternatives Shuttle Pharmaceuticals Alternatives Evoke Pharma Alternatives Lixte Biotechnology Alternatives IM Cannabis Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EVFM) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredHarris Pushes Radical Tax Hikes, Digital Currency—Your Money at Risk!First they attempted to silence Trump with a blatant attack. Now Joe Biden, the puppet president, has stepp...Oasis Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evofem Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evofem Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
